Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cardiff Oncology (Nasdaq: CRDF) announced the dosing of the first patient in its Phase 2 ONSEMBLE trial of onvansertib, aimed at treating KRAS/NRAS-mutated metastatic colorectal cancer (mCRC). This trial seeks to demonstrate a significant improvement in treatment response when combining onvansertib with the standard of care, FOLFIRI/bevacizumab. The primary endpoint focuses on objective response rates, while secondary endpoints include progression-free survival and overall survival. The trial is being conducted at nearly half of the planned 40 sites in the U.S., showing strong interest from investigators.
Cardiff Oncology (Nasdaq: CRDF) announced the formal introduction of its Scientific Advisory Board (SAB) on March 6, 2023. The SAB consists of esteemed leaders in oncology drug development and will guide the advancement of onvansertib, the company's lead asset targeting various cancers, including metastatic colorectal and pancreatic cancers. Notable members include Dr. Scott Kopetz and Dr. Heinz-Josef Lenz, among others, who bring extensive expertise in clinical research. The SAB is expected to expand its membership to enhance expertise in new clinical indications, reinforcing Cardiff's commitment to improving cancer treatment options.